Vizient, a healthcare performance improvement company, recently voiced its concerns to the Office of the United States Trade Representative about proposed tariffs on Chinese products.
Vizient, a healthcare performance improvement company, recently voiced its concerns to the Office of the United States Trade Representative (USTR) about proposed tariffs on Chinese products.
The original list of products affected by the tariffs, published last month by the USTR, comprised more than 1300 Chinese products worth about $50 billion each year. Included in the list were key ingredients used by drug makers to produce products including insulin, epinephrine, antibiotics, vaccines, and immunological products, as well as some medical devices.
However, China and the United States are currently in negotiations with regard to the tariffs. Despite the fact that talks are continuing, the White House said yesterday that it will be releasing a revised list of products affected by the potential tariffs on June 15, 2018, and that will begin imposing the tariffs “shortly thereafter.”
According to Vizient’s letter, while well-intentioned, USTR’s proposals could inadvertently impact the healthcare industry and the supply chain, because China is a major provider of raw ingredients that US drugmakers need.
Jody Hatcher, MBA, president of sourcing and collaboration services for Vizient, told The Center for Biosimilars® in an email, “Our current concern is focused on both component parts (eg, for medical devices) and on various raw materials (eg, ingredients for drugs such as insulin, epinephrine, and vaccines), as well as other critical patient care products.”
Added Hatcher, “The hospitals we serve already face immense pressure to care for a growing population amid rising prices, tight resources, and thin margins. We are concerned that the USTR proposals could result in higher prices for products and services being paid by providers, patients, and all American taxpayers; and more importantly, these challenges to affordability and accessibility could potentially negatively impact patient care…We encourage the USTR to work with other healthcare industry stakeholders—especially providers—to take steps to ensure that the proposed tariffs do not adversely impact the healthcare industry,” said Hatcher.
In addition to the tariffs, the White House has also said that it will announce investment restrictions and enhanced export controls on Chinese individuals and entities to prevent the acquisition of American technology. These restrictions are set to be announced by June 30, 2018.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.